TG Therapeutics Inc

NASDAQ:TGTXUnited States

Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

PALM BEACH, Fla., June 11, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - In the last twenty years, the amount of people with multiple sclerosis (MS) in the United States has more than doubled. In 2000, it was estimated by the National Multiple Sclerosis Society that around 400,000 Americans had the disease. In 2017, that estimate had jumped to 900,000. Although estimates between studies differ, it's commonly accepted that about 800,000-900,000 individuals in the United States suffer from MS, out of a global population of 2-3 million total individuals with MS. The number of individuals with multiple sclerosis is rapidly increasing, and with no known cure, the demand for effective treatment has increased immensely. Reports from a National Institute of Health study conducted by Watson et. Al reveal that the current state of treatment for those suffering from MS is not generating positive outcomes for a majority of patients. When physicians who treated patients with multiple sclerosis were asked what the greatest unmet needs were with current disease modifying therapies (DMTs), they most frequently mentioned a lack of effectiveness in treating symptoms and effects, and failure to amply slow disease progression. For both primary and secondary progressive multiple sclerosis, in particular those with the non-active variant of the disease, patients frequently don't receive treatment or their condition continues to get worse in spite of receiving treatment with existing DMTs. The population, already underserved, has exploded in the past two decades, making the need for a new treatment more critical than ever before. Active biotech and pharma companies in the markets this week include Tiziana Life Sciences, Ltd. (NASDAQ: TLSA), Eli Lilly and Company (NYSE: LLY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), TG Therapeutics, Inc. (NASDAQ: TGTX).

TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Fireside chat scheduled for Tuesday, June 11, 2024, at 1:20 PM ET

NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Goldman Sachs 45(th) Annual Global Healthcare Conference, being held at the Loews Miami Beach Hotel, Miami Beach, FL on June 10-13, 2024. The fireside chat is scheduled to take place on Tuesday, June 11, 2024, at 1:20 PM ET.